Biopharma net-net — 40%+ Upside (at A$1.27)
PMV Pharmaceuticals is developing a cancer therapy targeting a rare mutation. At first glance, it looks like your typical micro-cap biopharma that is burning through tons of cash in ‘pursuit of science’. But there are a few dynamics here that make the situation pretty interesting. There’s an imminent catalyst with trial results expected soon, and two distinct ways to win. If the trial data is positive, PMVP could be a solid winner. If not, there’s still a credible chance of value realization through a strategic review, either voluntary or prompted by frustrated shareholders.
Here are the key aspects of this thesis:
- Discount to net cash is substantial. PMVP trades at a $72m market cap, versus $166m in cash as of Q1. The balance sheet is super clean, with no lease overhangs or hidden potential liabilities. Adjusting for cash burn and other costs, net cash should still be 52% above today’s market cap by Q3 and around 40% above by year-end. So based on net cash alone, the upside is meaningful and comes with some embedded downside protection.
- The company has only one asset in development. It is already in a pivotal Phase 2 trial. Thanks to fast-track designation and the rarity of the target mutation, the ongoing trial will serve as the basis for an NDA (i.e. there will not be any further Phase 3 studies).
- Interim results of the trial are expected “mid-2025”, which basically means any day now. The interim readout will include data from 50 of 114 patients and is seen as a make-or-break moment for the drug. Previous Phase 1/2 results seemed quite promising.
- The shareholder base is very active and ready to act against management. Last month shareholders voted down the board’s compensation plan (20m votes against vs 12m for), and both directors up for reelection received a striking number of withheld votes (one had 18.6m votes withheld vs 13m for). This doesn’t look like one of those biopharmas where management gets to play science indefinitely.
- BML Investment Partners disclosed a 6.3% stake in December 2024. Shareholders base also includes OrbiMed (12.5% stake), Sio Capital Management (7%) and ArrowMark Colorado (7%).
What makes this setup particularly interesting is that it’s not just a simple binary bet on trial success or failure. Even if the interim results disappoint, the odds of the company pivoting to a cash realization strategy are not insignificant.
Roughly 36% of the diluted share count voted against the board’s compensation plan (and re-election of one director) last month. The vote took place just ahead of upcoming interim results and sends a clear message for management not to screw around if interim data is bad. In that scenario, I’d expect significant pressure to shut down the trial quickly and launch a strategic review. While biopharma management teams aren’t typically incentivized to make such moves, we’ve seen it happen before (e.g. ELEV and EPIX), even without visible shareholder pressure that we see here. With only one drug in development, PMVP has little room to pivot or distract with a manufactured pipeline story.
What also stands out here is the presence of Richard Heyman as chairman. He’s a genuine biotech star, with a resume full of billion-dollar exits: Rayze Bio ($4bn, 2024), Vividion Therapeutics ($1.5bn, 2021), Amunix ($1bn, 2021), Aragon Pharmaceuticals ($1bn, 2014), and Seragon Pharmaceuticals ($1.7bn, 2014). He was a chairman and/or co-founder of most of these companies. He also co-founded and now chairs ORIC ($1bn market cap), and has contributed to the development of multiple FDA-approved therapies, including the prostate cancer blockbuster Erleada. A strong track record doesn’t always translate to shareholder-friendly behavior. However, in a situation like this (i.e. nano-cap with mounting shareholder pressure), someone with Heyman’s reputation is less likely to risk it just to squeeze a few more million in compensation.
Assuming a timely strategic review, my net cash estimate breaks down as follows:
So that’s one way to win. Now, let’s look at the other one.
PMVP’s drug potential
The company is developing rezatapopt, a first-in-class therapy targeting the p53 Y220C mutation. p53 is a protein that’s supposed to stop cells from turning cancerous. It keeps cell division in check and acts as a tumor suppressor. About half of all cancers involve some kind of p53 mutation, but there are lots of different types. Rezatapopt is specifically designed to address the Y220C mutation, which creates a cavity in the protein, destabilizing it and disabling its tumor-suppressing function. Rezatapopt docks to this cavity (fills it), which is supposed to restore the function of p53. That has been shown to induce tumor shrinkage, disease stabilization, or even complete responses. The Y220C mutation currently has no approved therapies and is found in roughly 1% of all cancers. The most common one is ovarian cancer, where prevalence of this specific mutation is around 2.9%. Overall, there are 14,000 estimated patients annually in the U.S.
In oncology, the main benchmark for whether a drug is working is the Overall Response Rate (ORR). It shows the percentage of patients whose tumors shrink (partial response) or disappear entirely (complete response). An ORR above 30% is generally seen as a strong result. This study of 1,800 solid tumor trials found that 89% of drugs with a 30%+ ORR ended up getting regulatory approval. And for trials with an ORR of 45% or higher, the approval rate was 100%.
In its 2023 Phase 1/2 trial, rezatapopt was tested in 77 patients. The study primarily focused on four cancers: ovarian, breast, lung, and endometrial. The once-daily 2000mg dose (which is being used in the current Phase 2 trial) delivered an overall ORR of 38%. In ovarian cancer patients specifically, the ORR was even higher at 47% (see this presentation). That’s a very solid result.
The time to response was also fast (about 1.5 months) and the duration of response was solid at 7 months. As Ladenburg Thalmann (sell-side firm) pointed out at the time, those metrics stack up well against other tumor-agnostic drugs that received accelerated approval:
The current data looks comparable to other tumor-agnostic accelerated approvals of pembrolizumab (2017), larotrectinib (2018), entrectinib (2019), selpercatinib (2020), and dostarlimab (2021), with ORR ranges of 34%-75%, DoR of 6+ months, and TTR ranges of 1.0-2.8 months.
Safety profile was also favorable:
The ongoing Phase 2 trial includes 114 patients, with interim data from the first 50 (about 40% of whom have ovarian cancer) expected shortly. An ORR of 30% or higher would generally be seen as a success.
Sell-side analysts have near-term price targets in the $5–$6/share range and estimate peak sales between $400m and $600m. Anything close to that would obviously be a massive success from current levels. Not all of them provide actual details, but Landenburg Thalmann estimated that rezatapopt could eventually be used by around 1,700 patients, with ~$300,000 annual net price per patient. The drug price assumption is apparently close to the median annual cost for new oncology treatments.
It was noted on SSI before that potential blockbuster drugs often get acquired at 3x or more peak sales (e.g. SWTX and SAGE write-ups). Rezatapopt isn’t in that category. It targets a rare mutation with a relatively small patient population and faces early-stage competition from several runner-ups. That explains why the near-term price targets remain below 1x peak sales (i.e. $5/share implies a $280m market cap). However, the bottom line is that if the trial data holds up, the upside could be significant.
Risks and other things worth noting
- The main risk is that the interim results land in a gray zone, i.e. not great, but not terrible. In that case, management might argue it’s worth continuing the trial through to the final readout at year-end. If shareholders go along with that, the company could keep burning cash, and the stock might drift lower, potentially below $1/share.
- There are currently no approved treatments for the p53 Y220C mutation, and rezatapopt is still an experimental drug with a small sample size. I guess, that helps explain the current valuation.
- There are a few early-stage competitors to keep an eye on: JAB-30355 (Jacobio Pharma) – in Phase 1/2, NTS-071 (Nutshell Therapeutics) – in Phase 1, FMC-220 (Frontier Medicines) – just wrapped up preclinical work. I haven’t found any public trial data for these yet.
- The board is staggered, so a full activist overhaul is effectively impossible. The bet here isn’t on prolonged proxy fights, but that meaningful shareholder pressure alone would be enough to steer management toward the right decision.
- PMVP also highlights a Phase 1b combo trial with Merck’s azacitidine, which began in Q1 2025, as part of its pipeline. This technically gives management a bit of cover to continue development even if the monotherapy fails, but that leeway looks pretty thin. A previous combo trial with Merck’s Keytruda was already shut down due to dose-limiting toxicities. If rezatapopt fails as a standalone, it’s hard to assign meaningful value to the azacitidine combo. Importantly, this combo trial is an investigator-initiated study, led and funded by MD Anderson Cancer Center—not PMVP. So again, there’s not much room for the company to keep dragging things out in “zombie mode” if the data doesn’t hold up.
Thanks, interesting idea. Quick question on the insiders, how do you interpret the recent sale of shares by senior managers (CEO, COO, CDO and CFO) on Jul 3rd at a price of circa USD 1.06? Transaction values were not particularly high, but it represented a material component (apart from CEO) of their current stake: -6% for the CEO, -19% for the COO, -27% for the CDO and -32% for the CFO.
Always look at the actual filings. These are shares sold to pay taxes over the vesting of RSU’s. All happens automatically.
Great, thanks very helpful.
Apologies the transaction date was actually Jul 1st (not Jul 3rd).
Thanks for sharing. So it sounds like the discount to net cash has about 2-3 quarters of cushion beyond year-end ($99.8 Q4 net cash – $71.6 market cap)/$9 quarterly cash burn. Re: gray zone risk of a “not great, not terrible” readout, it sounds like management might then still choose to chase the azacitidine combo for that length of time and potentially increase the cash burn in the process? My layman’s understanding (and personal experience) is that these monotherapies are not particularly sustainable, especially for refractive, advanced tumors, and therefore need to find a combo partner(s) to be effiacious, whether immunotherapy, chemo, etc.
I also come with a layman’s understanding. What do you mean by “sustainable”? Does the ORR that recently came in at 43% change this even though it is a monotherapy?
Sustainable probably refers to Duration of Response, here 6-7 months.
Generally then, after a patient’s cancer progresses, the trial treatment phase is over for that patient and she can move on to other treatments.
Q2 results have been released. The company expects to report pivotal Phase 2 trial interim results on September 10. Cash burn during the quarter stood at c. $21m, which is inching slightly above my combined Q2 / Q3 combined cashburn estimate of $36.5m.
https://www.bamsec.com/filing/95017025104587?cik=1699382
PMVP is now trading at only 11% discount to Q4 estimated net cash of $1.77/share.
So the market is pricing in a relatively optimistic outcome either from positive trial results or poor results but a fast strategic review and liquidation.
Is the margin of safety still sufficient at current price?
Seems far less interesting to me than it was a few months ago. Quickly approaching (or passing) liquidation value. Also some minor datapoints:
1. I think the data is slightly delayed and that’s usually a bad sign. The company planned to release data “in the middle of the year” as late as May. Maybe a bit of a stretch, but September 10 does not seem like the middle of the year to me.
2. The company also stated it “anticipates a New Drug Application submission by the end of 2026” and had a section under ‘Forward-Looking Statement’ about the timing of the NDA filing in every quarterly PR. They removed both statements in the May Q1 press release.
Some minor stuff, but in combination with the run-up I’m happily following this from the sidelines.
PVMP reported strong interim Phase 2 data and the stock is up 25% on the news (that’s on top of yesterday’s 10% run-up).
ORR (Overall Response Rate) came in at 33% across 97 patients, with the ovarian cancer cohort at 43% (n=44). Other cohorts were weaker (~20% ORR), except endometrial cancer at 60%, though that was based on just 5 patients.
As I explained in the write up:
Time to response, duration of response and safety profile also look compelling.
So these results are really looking good and the company now seems to have a solid chance at approval for the ovarian cancer treatment (for cases with p53 Y220C mutation). The FDA has asked for additional testing on ovarian cohort – likely just to expand the sample size a bit more. PVMP will run another 20–25 patient trial, with enrollment planned by Q1 2026, and NDA targeted by Q1 2027. Cash runway looks sufficient to get through NDA application without a raise.
The catalyst has now played out and the stock is 60% above the write-up levels. I am taking a win here and removing PMVP from active ideas.
What entry/exit price are you claiming?
The pitch is at 1.27 and as at the time of writing it’s trading at 1.46.
What am I missing?
When I wrote the comment, the share price was comfortably sitting at $2+/share on a heavy volume in pre-market trading. 20m shares changed hands before the market opened. Surprised it went down so much after the open.
See here: https://www.nasdaq.com/market-activity/stocks/pmvp
For those that missed the pre-market, what is your take from now on?
whats your thought on the sudden price collapse
I suspect a lot of PMVP investors were in it for the discount to cash in a liquidation scenario. The probability of a liquidation evaporated this morning and now they are exiting the stock.
I’m puzzled by yesterday’s volatile trading – super enthusiastic and heavy volume in pre-market and then fully giving up when the market opened. Maybe that was bots trading or someone ran a quick pump-dump scheme. No idea why there was such a stark difference between the two trading periods.
Any investment in PMVP now is a bet on drug approval and eventual commercialization success (or a buyout). In my eyes, the former looks quite likely given positive Phase 2 interim read, but I am not able to shed any light on the latter (commercialization prospects or value of the drug) and can only cite management and sell-side on that.
As Ian noted, the liquidation scenario is now off the table and that might be the reason why the stock sold off.
Another possible explanation is that the market got disappointed when it realized that only the ovarian cancer indication looks like a potential success, and it will take another 1.5 years to reach NDA filing. The p53 Y220C mutation itself is rare, with about 14k cases annually in the US. PMVP estimates that the ovarian subset is only around 1.7k patients across both the US and EU. Nevertheless ovarian was always the lead and highest prospect indication. The company’s results presentation yesterday cited a US market opportunity of $350–420m and a global opportunity of $520–630m, which lines up almost exactly with sell-side estimates (most of which carry $5–6/share targets).
OrbiMed filed to sell 2,283,654 shares yesterday.
Does anyone have any experience valuing a vehicle that doesn’t have enough cash to take a drug to market?
It seems the cash runway is tight but somewhat realistic to make it to the NDA in early 2027. So in order to take this drug to market they will need additional cash for sure, perhaps also makes sense to partner with a larger pharma to leverage their superior marketing capabilities.
So to me this is a question of how will the vehicle be valued whenever it does indeed require additional capital? I have a few ideas but perhaps someone with more experience in this can shed light?
I work at a biotech company (I’m not a scientist) and was discussing PMV with the 2 guys in Business Development (they also have degrees in biotech related fields). One looked into the recent trials and said that from what he saw the efficacy was very good but the durability was not good, that some patients relapsed after 6 months. I don’t know just how much research he did, but that is what he reported.
The drug industry has many companies that reverse split and sell shares to raise cash to fund the next couple quarters, and also companies that have a single successful drug while never becoming profitable.
I can think of a single (am sure there are more) profitable one-approved drug company, Harmony Biosciences, and their share price is and will remain depressed until they demonstrate they can bring another drug to approval. They have bought a few small assets and if they can get those approved, good for them. They recently had a FDA Refusal to File which is embarrassing.
I personally would only trust a company like PMV if management demonstrated responsible cost management – put their own financial future at risk as a sign of faith in future success. These people haven’t. The top people make $3-$6 hundred thousand cash annually, plus millions more in stock options.
Yet Americans will pay hundreds of thousands of dollars for the last few months of cancer treatment.
Tang filed a 13G with 9+% holding. 13G is used for a “passive” investment. Setup doesn’t seem right for his usual approach, because mgmt and BOD probably still hope they have a viable company.
https://www.sec.gov/Archives/edgar/data/1699382/000121465925014073/xslSCHEDULE_13G_X01/primary_doc.xml
Maybe Tang is trying to push PMVP to sell or partner with a larger player?
Master Tang at times does invest for the actual science.
Anyone knowledgeable still following PMVP?
Thoughts on todays news?